Advisors

Corporate Counsel

Julio Vega is a partner in the corporate practice at Morgan Lewis. He represents public and private companies in a broad range of industries, including biotechnology, medical devices, nanotechnology, advanced materials, software, networking, e-commerce, and fintech. Julio has experience counseling clients on venture capital and other private equity financing transactions, public offerings, mergers and acquisitions, joint ventures, strategic alliances, licensing, and corporate partnering transactions. He regularly counsels clients on general corporate, employee compensation, and corporate governance matters. Julio is also very active in the representation of startup and emerging growth companies in the life sciences and technology industries.   Julio graduated from The University of Pennsylvania, Wharton School of Business, 1985, B.S., Economics, and the  University of Pennsylvania Law School, 1988, J.D.

CEO of Bulbrook/Drislane Brokerage, a national distributor of financial products headquartered in the Boston area. For more than 30 years John has helped insurance agents, financial planners and brokers find the right insurance and annuity products to meet their clients’ needs. In the process, he has earned a reputation throughout the industry for his integrity, resourcefulness and hard work, all carried out in good humor. Representing more than 40 insurance and annuity companies with his business partner Rick Drislane, John is in the enviable position of being able to help his agents identify the best policy at the best value for situations both simple and complex.  John is the Lead Independent Trustee of the Pear Tree Mutual Fund Group, with nearly four billion dollars in managed assets.

Emotionally intelligent, entrepreneurial Executive in the pharmaceutical and biotechnology industry with multiple drugs approved and approaching approval. These products are projected to be multi-billion dollar products and have created over $6 billion in market capitalization. Built and led successful teams in pharmaceutical research and development with over three decades of experience. Leadership positions include Executive position in business development for a top tier research medical school, decade long tenure as Executive Committee member of a publicly traded company, SVP of Global Research, and SVP of Quality. Directed internal and external international relationships. Therapeutic areas include Rare Diseases, Hemophilia, Pain, Oncology, Antivirals.